229 related articles for article (PubMed ID: 30898512)
1. Absence of predictable long-term molecular effect of ulipristal acetate (UPA) on the endometrium.
Kolanska K; Varinot J; Canlorbe G; Bergeron C; Mekinian A; Capmas P; Koskas M; Daraï E; Aractingi S; Bendifallah S; Chabbert-Buffet N
Reprod Biomed Online; 2019 May; 38(5):825-834. PubMed ID: 30898512
[TBL] [Abstract][Full Text] [Related]
2. Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium.
Whitaker LH; Murray AA; Matthews R; Shaw G; Williams AR; Saunders PT; Critchley HO
Hum Reprod; 2017 Mar; 32(3):531-543. PubMed ID: 28130434
[TBL] [Abstract][Full Text] [Related]
3. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract][Full Text] [Related]
4. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
5. Ulipristal acetate for uterine fibroid-related symptoms.
Puchar A; Luton D; Koskas M
Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
[TBL] [Abstract][Full Text] [Related]
6. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Molecular Changes in Endometrium Associated With Chronic Use of Progesterone Receptor Modulators: Ulipristal Acetate Versus Mifepristone.
Kannan A; Bhurke A; Sitruk-Ware R; Lalitkumar PG; Gemzell-Danielsson K; Williams ARW; Taylor RN; Bagchi MK; Bagchi IC
Reprod Sci; 2018 Mar; 25(3):320-328. PubMed ID: 29241443
[TBL] [Abstract][Full Text] [Related]
8. Sonographic and hysteroscopic endometrial examination in women treated with ulipristal acetate: Exploratory findings at a tertiary referral center.
Gracia M; Nonell R; Ros C; Rius M; Quintas L; Martínez-Zamora MÁ; Carmona F
Eur J Obstet Gynecol Reprod Biol; 2019 Jan; 232():40-45. PubMed ID: 30468982
[TBL] [Abstract][Full Text] [Related]
9. Endometrial Effects of Prolonged Therapy with the Selective Progesterone Receptor Modulator Ulipristal Acetate: A Case Report.
Levy G; Elkas J; Armstrong AY; Nieman LK
J Reprod Med; 2016; 61(3-4):159-62. PubMed ID: 27172639
[TBL] [Abstract][Full Text] [Related]
10. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
11. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
12. Ulipristal acetate modulates the expression and functions of activin a in leiomyoma cells.
Ciarmela P; Carrarelli P; Islam MS; Janjusevic M; Zupi E; Tosti C; Castellucci M; Petraglia F
Reprod Sci; 2014 Sep; 21(9):1120-5. PubMed ID: 25001022
[TBL] [Abstract][Full Text] [Related]
13. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
14. Pathologic Changes in Uterine Leiomyomas After Extended Treatment With Ulipristal Acetate.
Chang MC; Latta E
Int J Gynecol Pathol; 2020 Mar; 39(2):146-151. PubMed ID: 30702466
[TBL] [Abstract][Full Text] [Related]
15. UPA effects on endometrium - what is the significance?
Pleş L; Sima RM; Carp D; Florescu C; Dimitriu MCT; Ionescu CA
Rom J Morphol Embryol; 2018; 59(4):1127-1132. PubMed ID: 30845294
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment.
Melis GB; Piras B; Marotto MF; Orru' MM; Maricosu G; Pilloni M; Guerriero S; Angiolucci M; Lello S; Paoletti AM
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):901-8. PubMed ID: 22681335
[TBL] [Abstract][Full Text] [Related]
17. Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system.
Berger C; Boggavarapu NR; Menezes J; Lalitkumar PG; Gemzell-Danielsson K
Hum Reprod; 2015 Apr; 30(4):800-11. PubMed ID: 25740886
[TBL] [Abstract][Full Text] [Related]
18. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Williams AR; Bergeron C; Barlow DH; Ferenczy A
Int J Gynecol Pathol; 2012 Nov; 31(6):556-69. PubMed ID: 23018219
[TBL] [Abstract][Full Text] [Related]
19. The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology.
Rozenberg S; Praet J; Pazzaglia E; Gilles C; Manigart Y; Vandromme J
Aust N Z J Obstet Gynaecol; 2017 Aug; 57(4):393-399. PubMed ID: 28567743
[TBL] [Abstract][Full Text] [Related]
20. Endometrial Changes in Surgical Specimens of Perimenopausal Patients Treated With Ulipristal Acetate for Uterine Leiomyomas.
Nogales FF; Crespo-Lora V; Cruz-Viruel N; Chamorro-Santos C; Bergeron C
Int J Gynecol Pathol; 2018 Nov; 37(6):575-580. PubMed ID: 28914672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]